Vedolizumab
- Generic Name
- Vedolizumab
- Brand Names
- Entyvio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943609-66-3
- Unique Ingredient Identifier
- 9RV78Q2002
- Background
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 intera...
- Indication
Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.
- Associated Conditions
- Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- University of Pennsylvania
- Registration Number
- NCT03237260
- Locations
- 🇺🇸
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
Autologous Stem Cell Transplant for Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Aaron Etra
- Target Recruit Count
- 50
- Registration Number
- NCT03219359
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT03196427
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Children's Center for Digestive Healthcare, Atlanta, Georgia, United States
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 89
- Registration Number
- NCT03138655
- Locations
- 🇺🇸
Children's Center for Digestive Healthcare, Atlanta, Georgia, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸University Hospitals Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
- Conditions
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Takeda
- Registration Number
- NCT03035058
A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02993783
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇫🇷Hopital Claude Huriez - CHU Lille, Lille cedex, Nord, France
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 4
- Registration Number
- NCT02954159
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Synergistic Effect of Vedolizumab and Pentoxifylline
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 37
- Registration Number
- NCT02953275
- Locations
- 🇺🇸
University of Miami Crohn's and Colitis Center, Miami, Florida, United States
Vedolizumab Induction May Prevent Celiac Enteritis
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- AGA Clinical Research Associates, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT02929316
- Locations
- 🇺🇸
AGA Clinical Research Associates, LLC, Egg Harbor Township, New Jersey, United States
🇺🇸Theresa Stevens, Egg Harbor Township, New Jersey, United States
Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02878083
- Locations
- 🇫🇷
Chu Angers, Angers, France
🇫🇷Chd Vendee, La Roche Sur Yon, France
🇫🇷Chu Nantes, Nantes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.